Dive Brief:

潜水简介：

Eli Lilly on Monday said it will acquire a drug plant from Nexus Pharmaceuticals to expand its manufacturing capacity for injectable medicines.

礼来公司周一表示，将从Nexus Pharmaceuticals收购一家制药厂，以扩大其注射剂生产能力。

Located in Pleasant Prairie, Wisconsin, the facility spans 84,000 square feet and recently passed inspection by the Food and Drug Administration. It doesn’t currently provide any contract manufacturing services, so will be dedicated to making Lilly drugs, the company said.

该设施位于威斯康星州的普莱森特大草原，占地84000平方英尺，最近通过了食品和药物管理局的检查。该公司表示，该公司目前不提供任何合同制造服务，因此将致力于生产礼来药品。

Lilly expects production could begin by the end of next year. Reached by BioPharma Dive, a company spokesperson declined to comment on whether the company’s popular medicines for obesity and diabetes would be made at the site.

礼来公司预计明年年底开始生产。BioPharma Dive联系到一位公司发言人，该发言人拒绝评论该公司治疗肥胖和糖尿病的流行药物是否会在现场生产。

Dive Insight:

潜水洞察：

Lilly’s investment in new manufacturing capacity comes as demand has surged for its obesity medicine Zepbound, which is sold as Mounjaro for the treatment of diabetes.

礼来公司对新生产能力的投资正值其肥胖药物Zepbound的需求激增之际，Zepbound被称为Mounjaro，用于治疗糖尿病。

Doses of both injectable drugs are currently in shortage through the end of June, according to a FDA database. Novo Nordisk’s rival obesity medicine Wegovy has limited availability, too, as the Danish drugmaker has also struggled to keep up with soaring prescription numbers.

根据FDA的数据库，截至6月底，这两种注射剂的剂量目前都短缺。诺和诺德的竞争对手肥胖药物Wegovy的供应也很有限，因为这家丹麦制药商也在努力跟上不断飙升的处方数量。

Last November, Lilly announced a planned $2.5 billion investment in a new manufacturing plant to increase its injectable drug supply, one week after the FDA approved Zepbound for obesity. The new facility in Germany will build on expansions by Lilly of its locations in Indiana and North Carolina.

去年11月，在FDA批准Zepbound治疗肥胖症一周后，礼来宣布计划投资25亿美元新建一家制造厂，以增加其注射药物供应。礼来在德国的新工厂将扩大其在印第安纳州和北卡罗莱纳州的工厂。

Demand for GLP-1 medicines like Zepbound and Wegovy could grow further as their makers prove the drugs’ benefit in a broader range of conditions. For example, in a recent study, Zepbound reduced sleep apnea events in people who are overweight or obese. Lilly said it plans by mid-year to ask for a label expansion from the FDA and other regulators..

对Zepbound和Wegovy等GLP-1药物的需求可能会进一步增长，因为它们的制造商证明了该药物在更广泛的条件下的益处。例如，在最近的一项研究中，Zepbound减少了超重或肥胖人群的睡眠呼吸暂停事件。礼来公司表示，计划在年中之前要求FDA和其他监管机构扩大标签。

Novo Nordisk has also been investing in manufacturing. In February, Novo’s controlling shareholder Novo Holdings agreed to take contract manufacturer Catalent private for $16.5 billion. In a related transaction, Novo Nordisk will pay its parent company $11 billion for three large Catalent plants.

诺和诺德也一直在投资制造业。2月，诺和诺德控股股东诺和诺德控股同意以165亿美元的价格将合同制造商Catalent私有化。在一项关联交易中，诺和诺德将向其母公司支付110亿美元，收购三家大型Catalent工厂。

Evercore ISI analyst Umer Raffat noted that the Catalent deal will give Novo more additional capacity than Lilly’s, but wrote that Lilly “may likely invest significantly more to build [the Nexus site] out further.”

Evercore ISI分析师Umer Raffat指出，与Catalent的交易将为Novo带来比礼来更多的额外产能，但他写道礼来“可能会投入更多资金进一步建设”

Nexus claims on its website to have invested $100 million in the facility.

Nexus在其网站上声称已在该设施中投资1亿美元。